Pulmonary Vascular Disease |

Physician Monitoring of Pulmonary Arterial Hypertension Subjects: Results From a Large U.S. Health Insurance Claims Database FREE TO VIEW

Vijay Joish, PhD; David Muccino, MD; Mark Golick, PharmD; Omar Minai*, MD
Author and Funding Information

Bayer HealthCare Pharmaceuticals, Wayne, NJ

Chest. 2012;142(4_MeetingAbstracts):814A. doi:10.1378/chest.1387759
Text Size: A A A
Published online


SESSION TYPE: Pulmonary Hypertension II

PRESENTED ON: Monday, October 22, 2012 at 04:00 PM - 05:30 PM

PURPOSE: Current treatment guidelines suggest that pulmonary arterial hypertension (PAH) patients should be monitored every 3-6 months as part of routine care and 3-4 months after initiation or changes in therapy. To assess monitoring of PAH patients and determine demographic differences among patients who are adequately monitored vs. not.

METHODS: Data for this study came from a large employer-based claims database. PAH patients were selected anytime between Jan 1, 2007 to Dec 31, 2009 based on at least two medical claims with an International Classification of Disease v9 (ICD-9) code of 416.0, a right heart catheterization and data for 12 months pre and a minimum of 12 to up to 36 months post index event. The first medical claim for PAH served as the index event. PAH monitoring was defined by an outpatient medical claim with an ICD-9 code of 416.0 post index event till end of study/follow-up. Adequacy of monitoring was determined by the guidelines published by the European Society of Cardiology. All patient demographic characteristics, including the specialization of physician at diagnoses, and co-existing conditions were assessed.

RESULTS: 1,281 PAH patients met study criteria with an average age of 63 years (SD=12.8), 67% females (n=858), and a mean follow up period of 748 days (SD=243). The average monitoring visits across the sample was 8 (SD=12.9). As per guidelines, 54% (n=697) met the criteria for adequate monitoring. Patients in the adequate monitoring group were significantly (p<.05) younger (62 vs. 64 years), and had higher percentage of females (70% vs. 64%) compared to those not adequately monitored. Cardiovascular-related comorbidity such as hypertension, rheumatic disease, and musculoskeletal system & connective disorders were equally distributed. However, ischemic heart disease was greater (p=0.008) in proportion among those not adequately monitored.

CONCLUSIONS: According to this study up to 46% of newly diagnosed PAH patients may be inadequately monitored.

CLINICAL IMPLICATIONS: Future research needs to look at the impact of monitoring on treatment and overall cost of managing this debilitating condition.

DISCLOSURE: Vijay Joish: Employee: Employee of sponsor of study, Bayer

David Muccino: Employee: Employee of sponsor of study, Bayer

Mark Golick: Employee: Employee of sponsor of study, Bayer

Omar Minai: Consultant fee, speaker bureau, advisory committee, etc.: Consultant on this project sponsored by Bayer

No Product/Research Disclosure Information

Bayer HealthCare Pharmaceuticals, Wayne, NJ




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543